Literature DB >> 10126492

Willingness to pay for antihypertensive therapy--further results.

M Johannesson1, P O Johansson, B Kriström, U G Gerdtham.   

Abstract

A measurement experiment regarding willingness to pay for antihypertensive therapy is reported. A new type of binary willingness to pay question is used, that allows for different degrees of certainty with respect to the responses. Mean willingness to pay is derived from a simple expected utility model and estimated using maximum likelihood methods. The estimated parameters are highly significant, with predicted signs, and imply a mean willingness to pay of about SEK 800 ($130) per month. The explanatory power of the equation that only includes 'certain' yes/no responses is, as expected, much higher than that of the equation where only 'uncertain' responses are included.

Mesh:

Year:  1993        PMID: 10126492     DOI: 10.1016/0167-6296(93)90042-d

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  14 in total

1.  Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996).

Authors:  B George; A Harris; A Mitchell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Economic evaluation in healthcare. A brief history and future directions.

Authors:  K Blumenschein; M Johannesson
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

3.  The impact of user charges on the consumption of drugs. Empirical evidence and economic implications.

Authors:  U G Gerdtham; M Johannesson
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

4.  Innovations in health care financing: new evidence on the prospect of community health insurance schemes in the rural areas of Ethiopia.

Authors:  Abay Asfaw; Joachim von Braun
Journal:  Int J Health Care Finance Econ       Date:  2005-09

Review 5.  A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?

Authors:  Tracey H Sach; Richard D Smith; David K Whynes
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 6.  Using the stated preference technique for eliciting valuations: the role of the payment vehicle.

Authors:  Dorte Gyrd-Hansen
Journal:  Pharmacoeconomics       Date:  2013-10       Impact factor: 4.981

7.  Determinants of willingness to pay for a new therapy in a sample of menopausal-aged women.

Authors:  Andrej Rasch; Jan-Marc Hodek; Claus Runge; Wolfgang Greiner
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

8.  Cancer patients' willingness to pay for blood transfusions at home: results from a contingent valuation study in a French cancer network.

Authors:  Nathalie Havet; Magali Morelle; Raphaël Remonnay; Marie-Odile Carrere
Journal:  Eur J Health Econ       Date:  2011-06-10

9.  Willingness to pay for adverse drug event regulatory actions.

Authors:  Jacoline Bouvy; Just Weemers; Huub Schellekens; Marc Koopmanschap
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

10.  Urge incontinence. Quality of life and patients' valuation of symptom reduction.

Authors:  R M O'Conor; M Johannesson; S L Hass; G Kobelt-Nguyen
Journal:  Pharmacoeconomics       Date:  1998-11       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.